123 related articles for article (PubMed ID: 33231931)
21. Segmental neurofibromatosis 1 with gonosomal mosaicism.
Kim SR; Kibbi N; Imaeda S
Int J Dermatol; 2019 Dec; 58(12):e255-e256. PubMed ID: 31286507
[No Abstract] [Full Text] [Related]
22. Simultaneous Detection of
Bianchessi D; Ibba MC; Saletti V; Blasa S; Langella T; Paterra R; Cagnoli GA; Melloni G; Scuvera G; Natacci F; Cesaretti C; Finocchiaro G; Eoli M
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32575496
[TBL] [Abstract][Full Text] [Related]
23. Whole-exome Sequencing Identified a Novel Frameshift Mutation of
Liu L; Qin J; Luo H
Ann Clin Lab Sci; 2018 Nov; 48(6):808-809. PubMed ID: 30610056
[No Abstract] [Full Text] [Related]
24. Neurofibromatosis 1.
Lynch TM; Gutmann DH
Neurol Clin; 2002 Aug; 20(3):841-65. PubMed ID: 12432832
[TBL] [Abstract][Full Text] [Related]
25. The spectrum of NF1 mutations in Korean patients with neurofibromatosis type 1.
Jeong SY; Park SJ; Kim HJ
J Korean Med Sci; 2006 Feb; 21(1):107-12. PubMed ID: 16479075
[TBL] [Abstract][Full Text] [Related]
26. One
Pacot L; Burin des Roziers C; Laurendeau I; Briand-Suleau A; Coustier A; Mayard T; Tlemsani C; Faivre L; Thomas Q; Rodriguez D; Blesson S; Dollfus H; Muller YG; Parfait B; Vidaud M; Gilbert-Dussardier B; Yardin C; Dauriat B; Derancourt C; Vidaud D; Pasmant E
Genes (Basel); 2019 Aug; 10(9):. PubMed ID: 31443423
[TBL] [Abstract][Full Text] [Related]
27. Noonan syndrome and neurofibromatosis type I in a family with a novel mutation in NF1.
Nyström AM; Ekvall S; Allanson J; Edeby C; Elinder M; Holmström G; Bondeson ML; Annerén G
Clin Genet; 2009 Dec; 76(6):524-34. PubMed ID: 19845691
[TBL] [Abstract][Full Text] [Related]
28. Molecular diagnosis of neurofibromatosis type 1: 2 years experience.
Griffiths S; Thompson P; Frayling I; Upadhyaya M
Fam Cancer; 2007; 6(1):21-34. PubMed ID: 16944272
[TBL] [Abstract][Full Text] [Related]
29. [Molecular genetic diagnosis of neurofibromatosis type I].
Polgár N; Komlósi K; Hadzsiev K; Illés T; Melegh B
Orv Hetil; 2011 Mar; 152(11):415-9. PubMed ID: 21362601
[TBL] [Abstract][Full Text] [Related]
30. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
[TBL] [Abstract][Full Text] [Related]
31. Neurofibromatosis type 1 (NF1): diagnosis and management.
Ferner RE; Gutmann DH
Handb Clin Neurol; 2013; 115():939-55. PubMed ID: 23931823
[TBL] [Abstract][Full Text] [Related]
32. Familial evaluation reveals a distinct genetic cause in a large Spanish family with neurofibromatosis 1 and hypertrophic cardiomyopathy.
Salazar-Mendiguchía J; Díez-López C; Claver E; Cesar S; Campuzano O; Sarquella-Brugada G; Monserrat L
Gene; 2020 Jul; 746():144658. PubMed ID: 32283115
[TBL] [Abstract][Full Text] [Related]
33. Quantification of NF1 transcripts reveals novel highly expressed splice variants.
Vandenbroucke I; Vandesompele J; De Paepe A; Messiaen L
FEBS Lett; 2002 Jul; 522(1-3):71-6. PubMed ID: 12095621
[TBL] [Abstract][Full Text] [Related]
34. Independent NF1 mutations in two large families with spinal neurofibromatosis.
Messiaen L; Riccardi V; Peltonen J; Maertens O; Callens T; Karvonen SL; Leisti EL; Koivunen J; Vandenbroucke I; Stephens K; Pöyhönen M
J Med Genet; 2003 Feb; 40(2):122-6. PubMed ID: 12566521
[No Abstract] [Full Text] [Related]
35. Comment on Intragenic inversions in NF1 gene as pathogenic mechanism in neurofibromatosis type 1.
Pacot L; Chansavang A; Jacques S; Laurendeau I; Hadjadj D; Ferkal S; Wolkenstein P; Vidaud D; Pasmant E
Eur J Hum Genet; 2023 Apr; 31(4):380-382. PubMed ID: 36732663
[No Abstract] [Full Text] [Related]
36. A new insight into our understanding of neurofibromatosis type 1?
Chimenti S
J Eur Acad Dermatol Venereol; 2004 May; 18(3):261. PubMed ID: 15096131
[No Abstract] [Full Text] [Related]
37. Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.
Young LC; Goldstein de Salazar R; Han SW; Huang ZYS; Merk A; Drew M; Darling J; Wall V; Grisshammer R; Cheng A; Allison MR; Sale MJ; Nissley DV; Esposito D; Ognjenovic J; McCormick F
Proc Natl Acad Sci U S A; 2023 Jan; 120(5):e2208960120. PubMed ID: 36689660
[TBL] [Abstract][Full Text] [Related]
38. Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions.
Mautner VF; Kluwe L; Friedrich RE; Roehl AC; Bammert S; Högel J; Spöri H; Cooper DN; Kehrer-Sawatzki H
J Med Genet; 2010 Sep; 47(9):623-30. PubMed ID: 20543202
[TBL] [Abstract][Full Text] [Related]
39. Genotype-phenotype data from a case series of patients with mosaic neurofibromatosis type 1.
Marwaha A; Malach J; Shugar A; Hedges S; Weinstein M; Parkin PC; Pope E; Lara-Corrales I; Kannu P
Br J Dermatol; 2018 Nov; 179(5):1216-1217. PubMed ID: 29957862
[No Abstract] [Full Text] [Related]
40. Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types.
Kang E; Kim YM; Seo GH; Oh A; Yoon HM; Ra YS; Kim EK; Kim H; Heo SH; Kim GH; Osborn MJ; Tolar J; Yoo HW; Lee BH
J Hum Genet; 2020 Jan; 65(2):79-89. PubMed ID: 31776437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
